RECRUITING

Longitudinal Tracking of Patients Diagnosed With Neurodegenerative Movement Disorders

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The purpose of this protocol is to create an active natural history cohort of patients with degenerative movement disorders, tracked in a clinical setting with clinical rating scales and neuroimaging. The overarching rationale is that neurodegenerative diseases may be heterogeneous, complex disorders. A new way of performing clinical trials in these patients may be in order and this protocol aims to build a longitudinally tracked clinical trial-ready cohort of patients. The purpose of this protocol is to establish an active natural history cohort of patients with neurodegenerative movement disorders who are deeply phenotyped and "clinical trial ready" across Mass General Brigham. After a thorough clinical diagnostic evaluation (this may include clinically indicated testing, for example MRI, FDG-PET, MIBG scan, polysomnography, genetic testing, autonomic function tests, inflammatory tests, skin biopsy) the investigators aim to achieve this through: 1. Longitudinal tracking of clinical progression through use of clinical scales including at the present time: UMSARS, BARS, MoCA and UPSIT, PROM, MDS-NMS, UPDRS, and SARA 2. Longitudinal tracking of disease progression through use of neuroimaging including at the present time: TSPO-PET and 3D MRI (see section 1.3) This is a pilot study designed to track patients with neurodegenerative movement disorders across Mass General Brigham through MRI and PET imaging modalities and clinical measures. Figure 5 represents the study design in detail. In short, subjects will be asked to visit Mass General Brigham every 6-9 months over the course of 18 months for imaging and clinical evaluation.

Official Title

Longitudinal Tracking of Patients Diagnosed With Neurodegenerative Movement Disorders

Quick Facts

Study Start:2023-03-01
Study Completion:2024-11-15
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT05486806

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:Not specified
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. 1. Clinical diagnosis of neurodegenerative movement disorder by consensus criteria including: MSA, ataxias, synuclein duplication, atypical parkinsonism
  2. 2. Male and female subjects aged 18 and up
  1. 1. Individuals with a known alternate neurologic disorder including: idiopathic PD, DLB, PSP, ALS, Alzheimer's, prion disease, frontotemporal dementia, seizure disorder, stroke, or brain tumor
  2. 2. Individuals with a previous head injury (with 15 minutes or greater loss of consciousness within the past 20 years)
  3. 3. Individuals with substance abuse, or substance abuse disorder
  4. 4. Brain MRI indicative of a significant abnormality (i.e. prior hemorrhage or infarct greater than 1 cm3, 3 or more lacunar infarcts, cerebral contusion, encephalomalacia, aneurysm, vascular malformation, subdural hematoma, hydrocephalus, space- occupying lesion).
  5. 5. Individuals with bipolar disease and schizophrenia
  6. 6. Concurrent medical conditions that contraindicate study procedures
  7. 7. Women who are pregnant, nursing, or seeking to become pregnant
  8. 8. Individuals with claustrophobia
  9. 9. Non-MRI compatible implanted devices
  10. 10. Corticosteroid treatment in the past four weeks
  11. 11. Low affinity binders to TSPO
  12. 12. Significant cognitive impairment (MoCA score ≤ 23) or poor understanding of study design

Contacts and Locations

Study Contact

Diego Rodriguez, MD
CONTACT
507-491-0272
drodriguez29@bwh.harvard.edu
Vikram Khurana, MD PhD
CONTACT
vkhurana@bwh.harvard.edu

Principal Investigator

Vikram Khurana, MD PhD
PRINCIPAL_INVESTIGATOR
Brigham and Women's Hospital

Study Locations (Sites)

Brigham and Women's Hospital
Boston, Massachusetts, 02115
United States

Collaborators and Investigators

Sponsor: Brigham and Women's Hospital

  • Vikram Khurana, MD PhD, PRINCIPAL_INVESTIGATOR, Brigham and Women's Hospital

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2023-03-01
Study Completion Date2024-11-15

Study Record Updates

Study Start Date2023-03-01
Study Completion Date2024-11-15

Terms related to this study

Additional Relevant MeSH Terms

  • Neurodegenerative Diseases
  • sca3
  • MSA - Multiple System Atrophy
  • Ataxia
  • Synucleinopathies